Abstract
To the Editor: At present, infections with herpes simplex viruses Types 1 and 2 have become epidemic. Herpes progenitalis (due to Types 1 and 2) is the most common venereally transmitted disease that we see in our dermatologic practice. The oncogenic potential of both Type 1 and Type 2 has already been reported.1 , 2 Recurrent herpes, gingivostomatitis, vulvovaginitis, keratoconjunctivitis, Kaposi's varicelliform eruption, encephalitis and neonatal herpes viremia are all well recognized problems induced by these viruses. Therapy has been frustrating, to say the least. An effective and safe therapeutic agent has always seemed just out of reach. Asculai et al.3 presented . . .